-+ 0.00%
-+ 0.00%
-+ 0.00%

NervGen prices 24,000,000-share offering with warrants at US$2.5, targets US$60 million gross proceeds

PUBT·06/01/2026 21:30:14
Listen to the news
NervGen prices 24,000,000-share offering with warrants at US$2.5, targets US$60 million gross proceeds
  • NervGen priced an underwritten follow-on public offering of 24,000,000 common shares with warrants to buy up to 24,000,000 shares.
  • Offering price set at US$ 2.5 per common share and accompanying warrant; gross proceeds about US$ 60 million, excluding warrant exercises.
  • Warrants carry a US$ 3.68 exercise price, are immediately exercisable, and expire five years from issuance.
  • Net proceeds earmarked to advance NVG-291 clinical studies, with remaining funds for general corporate purposes.
  • PFP Biosciences participated; post-offering stake 15,488,673 shares (14.58%) with 8,144,335 warrants, capped at 19.99% ownership on exercise.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NervGen Pharma Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-069028), on June 01, 2026, and is solely responsible for the information contained therein.